Glenmark Pharmaceuticals Licences Small Molecule Oncology Compound from APC Therapeutics

0
871
Mumbai, June 22, 2017: Pharma Major Glenmark Pharmaceuticals today said that company has entered into a licencing agreement with the Boston-based APC Therapeutics Inc.

APC Therapeutics Inc is a biopharmaceutical company focused on building a portfolio of best-in-class immuno-oncology (IO) therapies, for exclusive rights to a small molecule, oncology compound based on Antigen Presenting Cell (APC) biology, company release said.

United News of India